CD38 inhibitor 78c is primarily explored for its potential in targeting diseases where CD38 activity plays a critical role. One of its key applications is in the treatment of multiple myeloma, a type of blood cancer, where CD38 is highly expressed on malignant plasma cells. By inhibiting CD38, it helps in reducing tumor growth and promoting cancer cell death. Additionally, it is being investigated for its role in autoimmune diseases and inflammatory conditions, as CD38 is involved in immune cell signaling and inflammation. Its ability to modulate NAD+ metabolism also makes it a candidate for research in age-related diseases and metabolic disorders.